TXG

10x Genomics, Inc. (TXG) - 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2025. 10x Genomics is a life sciences technology company providing integrated research solutions (instruments, consumables, and software) for single-cell and spatial biology analysis. The company operates globally with a focus on academic, government, and biopharmaceutical customers. In August 2025, the company completed the acquisition of Scale Biosciences, Inc. ("Scale Bio"), accounted for as an asset acquisition, to expand its single-cell portfolio.

Key Financial Metrics

Revenue Composition (2025): Products and services revenue was $596.7 million (down 2% YoY), while License and royalty revenue was $46.1 million (up significantly due to litigation settlements). Consumables revenue grew 3% to $507.2 million, offset by a 39% decline in instrument revenue.

Material Changes vs. Prior Period

• Revenue Mix Shift: Total revenue grew 5% primarily driven by non-recurring license and royalty revenue of $46.1 million from settlements with Vizgen ($16.8M) and Bruker ($27.3M). Excluding these settlements, core product revenue declined.
• Instrument Sales Decline: Instrument revenue dropped 39% to $56.8 million due to price decreases and lower volume of Spatial instruments sold.
• Consumables Growth: Spatial consumables revenue increased 19% to $144.0 million, partially offset by a 2% decline in Single Cell consumables revenue.
• Expense Reduction: Operating expenses decreased 17% to $504.9 million. This included a $49.9 million "Gain on settlement" (non-operating income) and reduced R&D and SG&A spending due to restructuring and cost management.
• Inventory Write-downs: The company recorded $26.5 million in excess and obsolete inventory charges in 2025, compared to $11.3 million in 2024.
• Acquisition: Acquired Scale Bio for an upfront payment of $9.2 million cash and $13.5 million in stock, with potential contingent consideration up to $30.0 million.

Guidance, Outlook, and Risks

Outlook: Management expects revenues to moderately increase in 2026 compared to 2025, excluding the $44.1 million of non-recurring revenue from patent litigation settlements in 2025. Operating expenses are expected to modestly decrease in 2026. The company anticipates continuing to incur operating losses in the near term but believes existing cash resources are sufficient for at least the next 12 months.

Key Risks and Contingencies:

• Government Funding Dependency: A substantial portion of revenue relies on academic and government funding (e.g., NIH). Recent NIH funding pauses, indirect cost caps, and grant terminations in 2025 have caused delays and reductions in customer spending.
• Regulatory Environment: Products are currently "Research Use Only" (RUO). Expansion into clinical/diagnostic markets would subject the company to onerous FDA and EU IVDR regulations.
• Intellectual Property Litigation: The company is actively involved in patent litigation (e.g., against Parse, Curio, and Illumina). While settlements with Vizgen and Bruker were favorable, ongoing litigation outcomes remain uncertain.
• Supply Chain and Manufacturing: Risks include reliance on single-source suppliers for critical reagents and enzymes, and potential disruptions from tariffs or geopolitical tensions (specifically U.S.-China trade relations).
• Product Transition: Revenue from the core Chromium platform decreased year-over-year. Success depends on the adoption of new products and the Scale Bio integration.

Investor Verification Checklist

• Sustainability of Revenue Growth: Verify if the 5% revenue growth is sustainable without the $44.1 million in non-recurring litigation settlement revenue.
• Instrument Sales Trajectory: Investigate the reasons for the 39% drop in instrument revenue and whether price reductions are successfully driving future consumable volume.
• NIH Funding Impact: Assess the long-term impact of NIH funding uncertainties and indirect cost caps on the academic customer base.
• Scale Bio Integration: Monitor the integration progress of Scale Bio and the realization of expected synergies in the single-cell portfolio.
• Inventory Management: Review future inventory write-down risks given the $26.5 million charge in 2025 and the company's history of product transitions.
• Cash Burn vs. Cash Flow: Confirm the company's ability to maintain positive operating cash flow as it invests in R&D and commercial expansion.